Manages well-differentiated thyroid cancer Thyroid Suppression Test. ANDA 218070, held by Biocon Pharma. Liothyronine Sodium.
As of Nov 16, 2026, ANDA 218070 (Liothyronine Sodium), held by Biocon Pharma, was first approved by FDA on Feb 6, 2024, with 0 approved supplements and 0 published complete response letters.
Liothyronine is an L-triiodothyronine (T3) indicated for: Hypothyroidism: As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism Pituitary Thyroid-Stimulating Hormone (TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer Thyroid Suppression Test: As a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy Limitations of Use: - Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 6, 2024 | Original application | Approved | None posted |
| Liothyronine SodiumEQ 0.005MG BASE · tablet;oral | Liothyronine Sodium | Rx |
| Liothyronine SodiumEQ 0.025MG BASE · tablet;oral | Liothyronine Sodium | Rx |
| Liothyronine SodiumEQ 0.05MG BASE · tablet;oral | Liothyronine Sodium | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters